Abner Herrman & Brock LLC Purchased 48 Shares of Becton Dickinson and Co (BDX)

Abner Herrman & Brock LLC Purchased 48 Shares of Becton Dickinson and Co (BDX)

Abner Herrman & Brock LLC grew its stake in Becton Dickinson and Co (NYSE:BDX) by 4.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,105 shares of the medical instruments supplier’s stock after buying an additional 48 shares during the quarter. Abner Herrman & Brock LLC’s holdings in Becton Dickinson and were worth $249,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Cullinan Associates Inc. purchased a new position in shares of Becton Dickinson and in the 4th quarter valued at about $248,000. New England Research & Management Inc. purchased a new position in shares of Becton Dickinson and in the 4th quarter valued at about $854,000. First Hawaiian Bank boosted its stake in shares of Becton Dickinson and by 30.3% in the 4th quarter. First Hawaiian Bank now owns 10,000 shares of the medical instruments supplier’s stock valued at $2,253,000 after buying an additional 2,323 shares during the period. Mitchell Mcleod Pugh & Williams Inc. lifted its stake in Becton Dickinson and by 1.2% during the fourth quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 4,123 shares of the medical instruments supplier’s stock worth $929,000 after purchasing an additional 47 shares during the last quarter. Finally, Alta Capital Management LLC purchased a new stake in Becton Dickinson and during the fourth quarter worth approximately $30,124,000. Institutional investors and hedge funds own 83.77% of the company’s stock.

Several research firms recently weighed in on BDX. Morgan Stanley boosted their target price on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 4th. UBS Group began coverage on Becton Dickinson and in a research note on Tuesday, November 27th. They set a “neutral” rating and a $260.00 target price for the company. Deutsche Bank began coverage on Becton Dickinson and in a research note on Thursday, December 6th. They set a “buy” rating and a $280.00 target price for the company. Wells Fargo & Co decreased their target price on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, November 7th. Finally, Piper Jaffray Companies decreased their target price on Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, November 6th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Buy” and an average price target of $251.85.

BDX traded down $2.30 during trading on Friday, hitting $227.15. 24,036 shares of the stock were exchanged, compared to its average volume of 1,235,191. The firm has a market cap of $61.02 billion, a price-to-earnings ratio of 20.64, a price-to-earnings-growth ratio of 1.63 and a beta of 1.21. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 0.90.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, hitting the consensus estimate of $2.93. The company had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a return on equity of 13.88% and a net margin of 1.47%. The firm’s revenue was up 39.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.40 earnings per share. Equities analysts expect that Becton Dickinson and Co will post 12.11 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Monday, December 31st. Stockholders of record on Monday, December 10th were issued a $0.77 dividend. The ex-dividend date of this dividend was Friday, December 7th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.36%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.75. Becton Dickinson and’s payout ratio is presently 27.97%.

In other news, CEO Vincent A. Forlenza sold 16,866 shares of the business’s stock in a transaction that occurred on Tuesday, November 13th. The stock was sold at an average price of $237.61, for a total value of $4,007,530.26. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP James W. Borzi sold 5,887 shares of the business’s stock in a transaction that occurred on Friday, November 30th. The shares were sold at an average price of $252.37, for a total value of $1,485,702.19. Following the completion of the transaction, the executive vice president now directly owns 6,013 shares in the company, valued at approximately $1,517,500.81. The disclosure for this sale can be found here. In the last three months, insiders sold 81,795 shares of company stock worth $19,571,318. Corporate insiders own 0.12% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: Asset Allocation Models, Which is Right For You?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Related posts

Leave a Comment